Clinical Trial Detail

NCT ID NCT01006369
Title Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors Rutgers, The State University of New Jersey
Indications

colorectal cancer

Therapies

Hydroxychloroquine

Capecitabine + Oxaliplatin + Bevacizumab

Bevacizumab + FOLFOX

Age Groups: adult

No variant requirements are available.